MA55801A - Formes solides d'un inhibiteur de glyt1 - Google Patents
Formes solides d'un inhibiteur de glyt1Info
- Publication number
- MA55801A MA55801A MA055801A MA55801A MA55801A MA 55801 A MA55801 A MA 55801A MA 055801 A MA055801 A MA 055801A MA 55801 A MA55801 A MA 55801A MA 55801 A MA55801 A MA 55801A
- Authority
- MA
- Morocco
- Prior art keywords
- solid forms
- glyt1 inhibitor
- glyt1
- inhibitor
- solid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841401P | 2019-05-01 | 2019-05-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA55801A true MA55801A (fr) | 2022-03-09 |
Family
ID=70740812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA055801A MA55801A (fr) | 2019-05-01 | 2020-04-30 | Formes solides d'un inhibiteur de glyt1 |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US11447474B2 (fr) |
| EP (1) | EP3962911A1 (fr) |
| JP (2) | JP7513349B2 (fr) |
| KR (1) | KR20220004174A (fr) |
| CN (1) | CN113784966B (fr) |
| AR (1) | AR118839A1 (fr) |
| AU (1) | AU2020266566B2 (fr) |
| BR (1) | BR112021020883A2 (fr) |
| CA (1) | CA3138288A1 (fr) |
| CL (2) | CL2021002837A1 (fr) |
| CO (1) | CO2021014260A2 (fr) |
| CR (1) | CR20210545A (fr) |
| DO (1) | DOP2021000224A (fr) |
| EA (1) | EA202192925A1 (fr) |
| EC (1) | ECSP21082195A (fr) |
| IL (1) | IL287630A (fr) |
| JO (1) | JOP20210295A1 (fr) |
| MA (1) | MA55801A (fr) |
| MX (1) | MX2021013341A (fr) |
| PE (1) | PE20212263A1 (fr) |
| PH (1) | PH12021552741A1 (fr) |
| SG (1) | SG11202111972YA (fr) |
| TW (1) | TW202106680A (fr) |
| UA (1) | UA129159C2 (fr) |
| WO (1) | WO2020223419A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7930336B2 (en) | 2006-12-05 | 2011-04-19 | Altera Corporation | Large multiplier for programmable logic device |
| CN113784966B (zh) * | 2019-05-01 | 2024-07-19 | 勃林格殷格翰国际有限公司 | Glyt1抑制剂的固体形式 |
| KR20220125326A (ko) | 2020-01-09 | 2022-09-14 | 디스크 메디슨, 인크. | 적혈구형성 프로토포르피린증, x-연계된 프로토포르피린증, 또는 선천성 적혈구 조혈포르피린증을 글리신 운반 억제제로 치료하는 방법 |
| CA3188340A1 (fr) | 2020-08-13 | 2022-02-17 | Boehringer Ingelheim International Gmbh | Traitement de la deficience cognitive associee a la schizophrenie |
| CA3195702A1 (fr) | 2020-10-13 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Procede de retraitement |
| WO2025140479A1 (fr) * | 2023-12-29 | 2025-07-03 | 苏州科睿思制药有限公司 | Forme cristalline d'iclépertine, son procédé de préparation et son utilisation |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL65843A (en) * | 1977-08-11 | 1986-12-31 | American Cyanamid Co | Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type |
| KR20060095865A (ko) * | 2003-10-14 | 2006-09-04 | 화이자 프로덕츠 인크. | 글리신 수송 억제제로서의 비시클릭 [3.1.0] 유도체 |
| BRPI0922787A2 (pt) * | 2008-12-04 | 2017-07-11 | Sanofi Sa | Formas polimórficas de um derivado da azabiciclo-trifluorometil benzamida |
| WO2010078348A1 (fr) * | 2008-12-29 | 2010-07-08 | Vanderbilt University | Inhibiteurs de glyt1 bicyclique et leurs procédés de production et d'utilisation |
| US9012489B2 (en) | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| CA3061600A1 (fr) * | 2017-04-27 | 2019-10-25 | Takeda Pharmaceutical Company Limited | Compose heterocyclique |
| CN113784966B (zh) | 2019-05-01 | 2024-07-19 | 勃林格殷格翰国际有限公司 | Glyt1抑制剂的固体形式 |
| CA3188340A1 (fr) * | 2020-08-13 | 2022-02-17 | Boehringer Ingelheim International Gmbh | Traitement de la deficience cognitive associee a la schizophrenie |
| CA3195702A1 (fr) * | 2020-10-13 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Procede de retraitement |
-
2020
- 2020-04-30 CN CN202080032902.7A patent/CN113784966B/zh active Active
- 2020-04-30 PE PE2021001800A patent/PE20212263A1/es unknown
- 2020-04-30 PH PH1/2021/552741A patent/PH12021552741A1/en unknown
- 2020-04-30 EA EA202192925A patent/EA202192925A1/ru unknown
- 2020-04-30 DO DO2021000224A patent/DOP2021000224A/es unknown
- 2020-04-30 MX MX2021013341A patent/MX2021013341A/es unknown
- 2020-04-30 BR BR112021020883A patent/BR112021020883A2/pt unknown
- 2020-04-30 AU AU2020266566A patent/AU2020266566B2/en active Active
- 2020-04-30 EP EP20726654.5A patent/EP3962911A1/fr active Pending
- 2020-04-30 US US16/862,608 patent/US11447474B2/en active Active
- 2020-04-30 MA MA055801A patent/MA55801A/fr unknown
- 2020-04-30 UA UAA202106566A patent/UA129159C2/uk unknown
- 2020-04-30 WO PCT/US2020/030580 patent/WO2020223419A1/fr not_active Ceased
- 2020-04-30 KR KR1020217039503A patent/KR20220004174A/ko not_active Ceased
- 2020-04-30 JP JP2021563717A patent/JP7513349B2/ja active Active
- 2020-04-30 JO JOP/2021/0295A patent/JOP20210295A1/ar unknown
- 2020-04-30 CR CR20210545A patent/CR20210545A/es unknown
- 2020-04-30 AR ARP200101242A patent/AR118839A1/es unknown
- 2020-04-30 CA CA3138288A patent/CA3138288A1/fr active Pending
- 2020-04-30 SG SG11202111972YA patent/SG11202111972YA/en unknown
- 2020-04-30 TW TW109114685A patent/TW202106680A/zh unknown
-
2021
- 2021-10-26 CO CONC2021/0014260A patent/CO2021014260A2/es unknown
- 2021-10-27 IL IL287630A patent/IL287630A/en unknown
- 2021-10-28 CL CL2021002837A patent/CL2021002837A1/es unknown
- 2021-11-17 EC ECSENADI202182195A patent/ECSP21082195A/es unknown
-
2022
- 2022-06-27 US US17/849,935 patent/US20220332710A1/en not_active Abandoned
-
2024
- 2024-03-21 CL CL2024000829A patent/CL2024000829A1/es unknown
- 2024-05-02 JP JP2024074707A patent/JP7714727B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA55801A (fr) | Formes solides d'un inhibiteur de glyt1 | |
| MA54526A (fr) | NOUVELLES FORMES POLYMORPHES D'UN INHIBITEUR DE TGFBeta | |
| EP3924352A4 (fr) | Formes cristallines d'un inhibiteur rsk | |
| IL282682A (en) | Improved synthesis of key intermediate of kras g12c inhibitor compound | |
| MA54458A (fr) | Formes cristallines et formes salines d'un inhibiteur de kinase | |
| EP3870178A4 (fr) | Formes cristallines d'inhibiteurs de mnk | |
| EP3893891A4 (fr) | Formes solides d'un inhibiteur de cd73 et leur utilisation | |
| MA52493A (fr) | Sels d'un inhibiteur de fgfr | |
| PT4058453T (pt) | Síntese melhorada de composto inibidor de kras g12c | |
| EP3947361A4 (fr) | Sel et forme cristalline d'un inhibiteur de fak | |
| MA53226A (fr) | Sel et formes cristallines d'omecamtiv mecarbil | |
| EP3841465A4 (fr) | Structures de prédiction de branchement filtrées d'un processeur | |
| EP3870181A4 (fr) | Formes cristallines d'un inhibiteur d'alk2 | |
| MA55614A (fr) | Formes cristallines d'inhibiteur de pyridazinone trpc | |
| EP3509594A4 (fr) | Utilisations d'un inhibiteur d'homologue 2 de lysyl-oxydase | |
| EP3807279A4 (fr) | Sels pharmaceutiquement acceptables de sépiaptérine | |
| MA52004A (fr) | Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase | |
| EP3619208C0 (fr) | Formes cristallines d'un composé inhibiteur de jak | |
| EP3782987A4 (fr) | Composé de benzo-pyrazole tenant lieu d'inhibiteur de la rho-kinase | |
| EP3919491A4 (fr) | Inhibiteur d'akt | |
| MA56001A (fr) | Formes de sel cristallin d'un inhibiteur de kinase | |
| EP4337203A4 (fr) | Inhibiteurs de l'interaction ménine-mll | |
| EP4263488A4 (fr) | Formes solides d'un composé | |
| EP4003986A4 (fr) | Composés inhibiteurs | |
| EP3877475A4 (fr) | Compositions synergiques d'inhibiteur de corrosion |